If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
196
results.
Updated on
06/11/2025 [06:52:00]
Results 125 to 150 of 196
Absstract of: CN120837451A
本发明涉及核酸药物制剂技术领域，公开了一种基于积雪草酸的脂质纳米颗粒及其制备方法与应用，该脂质纳米颗粒由摩尔比为10‑85：20‑60：1‑30：0.1‑10：0.1‑50的可电离的阳离子脂质、结构脂质、中性脂质、PEG脂质和积雪草酸组成以作为核酸药物的递送载体，用于递送核酸药物。本发明创新性地采用天然产物积雪草酸部分替代传统LNP配方中的结构脂质（如胆固醇），显著优化了其微观形态，从而大幅增强了mRNA在体内外的转染与表达效率。基于该载体构建的mRNA疫苗可诱导机体产生高滴度的特异性抗体，显著增强细胞毒性T淋巴细胞（CTL）杀伤活性。该LNP系统在肿瘤免疫预防与治疗领域表现突出，展现出优越的转化应用潜力和广阔的市场前景。
Absstract of: CN120837450A
本发明涉及一种脂质纳米颗粒制剂，具体涉及包含脂质体和荷载的脂质纳米颗粒，所述脂质体包括靶向功能脂质和脂质载体组分。本发明还涉及所述脂质纳米颗粒制剂在治疗或预防与动脉粥样硬化相关的疾病的药物中的用途。
Absstract of: CN120837448A
本发明提供了一种靶向肿瘤的光控化学生成过氧亚硝酸根的纳米产生器及其制备方法和应用，靶向肿瘤的光控化学生成过氧亚硝酸根的纳米产生器包括内核以及包覆所述内核的包覆层，所述内核包括负载BNN‑6的普鲁士蓝，所述包覆层包括肿瘤细胞膜。本发明能够实现近红外I区光照射下对肿瘤细胞的特异性产生ONOO‑，抑制丙酮酸激酶（PK）和谷氨酰胺酶（GLS）的活性，破坏肿瘤细胞的糖酵解和谷氨酰胺代谢。
Absstract of: CN120842103A
本发明公开了含氮链状化合物、制备方法、包含其的组合物和应用。本发明具体公开了一种化合物I或其药学上可接受的盐。采用本发明的含氮链状化合物制备得到的LNP制剂，纳米颗粒大小相对均匀，包封率较高，体内表达活性较高。
Absstract of: AU2025203403A1
0324 The present invention provides compositions comprising peptide-coupled biodegradable poly(lactide-co-glycolide) (PLG) particles In particular, PLG particles are surface-functionalized to allow for coupling of peptide molecules to the surface of the particles (e.g., for use in eliciting induction of immunological tolerance).
Absstract of: GB2626698A
A pharmaceutical composition comprising: (a) a recombinant nucleic acid, wherein the recombinant nucleic acid comprises a sequence encoding a chimeric fusion protein (CFP), the CFP comprising: an extracellular domain comprising an anti-GPC3 binding domain, a transmembrane domain of FcRα or FcRβ operatively linked to the extracellular domain; an intracellular domain comprising one or more intracellular signaling domains; and(b) a pharmaceutically acceptable carrier; wherein the CFP forms a functional complex with FcRγ in myeloid cells.
Absstract of: CN120827844A
本发明涉及生物技术和基因工程技术领域，其公开了用于脂质纳米颗粒合成的被动式微通道反应器及其应用，其包括反应器本体和反应器盖板，反应器本体内嵌设有凹陷呈Y字型的流道，包括供第一种液体进入的第一进液口、第一进液口通道、供第二种液体进入第二进液口、第二进液口通道、混流通道、在混流通道末端用于形成稳态出液流的出液口通道和出液口；混流通道内设有用于螺旋扰流的螺旋混流芯片；反应盖板上设有上设有三个接口，第一进液转接头与第一进液口对应连通；第二进液转接头与第二进液口对应连通；出液转接头与出液口对应连通。本发明的流道结构简单，利于大规模制造易清洁，且产物粒径分布均一性好，灵活地适配各种类型的动力系统。
Absstract of: CN120827533A
本发明公开了一种靶向β淀粉样蛋白降解的纳米颗粒及其制备方法和应用。所述纳米颗粒包括共价连接的透明质酸、聚乙二醇和GKLVFFK多肽。GKLVFFK多肽的结构相对稳定，有利于与Aβ形成稳定的复合物，同时具备低免疫原性和毒副作用；透明质酸同时作为纳米颗粒的骨架和靶向单元，通过靶向细胞表面的CD44受体，可以将目标蛋白介导进入细胞的溶酶体降解通道；基于透明质酸骨架上缀合的PEG的亲疏水作用自主形成纳米颗粒；各单元整体配合，实现抑制和减缓致病蛋白Aβ的积累，有望为AD患者带来实质性的治疗效果。
Absstract of: CN120829373A
本发明提供了一种用于肺部选择性药物递送的脂质化合物及其制备方法和应用。本发明的脂质化合物的结构通式如式Ⅰ所示。本发明的脂质化合物可用于制备脂质纳米颗粒或用于构建生物大分子递送体系。本发明构建的生物大分子递送体系可用于肺部选择性多种大分子如蛋白质递送的通用平台，且构建的生物大分子递送体系的工艺简单，原料廉价易得，通过投射电镜观察可见所形成的脂质纳米颗粒的粒径均一。
Absstract of: CN120827557A
本发明提供基于硫辛酸的纳米酶及其制备方法与应用，首先利用硫辛酸的两亲性使其溶于有机溶剂并在水中自组装形成纳米聚集体，再由紫外光照引发硫辛酸开环聚合即得到稳定的硫辛酸纳米粒子，即基于硫辛酸的纳米酶。本发明的有益效果是：利用本发明方法制备得到的基于硫辛酸的纳米酶制备方法简单，且同时具备稳定的粒径、良好的活性氧清除能力以及跨越血脑屏障的能力，此外纳米酶内部的空腔适于负载疏水性的生物活性因子及药物，纳米酶表面丰富的羧基可与多种离子进行络合，可应用于治疗缺氧或缺血等引起的炎症类疾病以及脑部药物递送。
Absstract of: WO2024144009A1
The present invention relates to: ionized lipids comprising lipids with a branched structure; a lipid nanoparticle formulation using same; and use thereof. The ionized lipids of the present invention are a biodegradable lipid material with a lipid structure in which a heteroamine structure is branched, and the lipid nanoparticles using the ionized lipids can deliver a nucleic acid drug and the like with high efficiency, and thus can be effectively used in related technical fields such as mRNA vaccines and therapeutic agents.
Absstract of: AU2023368775A1
Provided herein is a lipid nanoparticle comprising an encapsulated oligonucleotide molecule, wherein the oligonucleotide molecule is single-stranded or double-stranded and has a length of between 5 and 500 nucleotides; and 20 to 70 mol% of a neutral lipid content relative to total lipid present in the lipid nanoparticle, an ionizable lipid; a sterol; and optionally a hydrophilic polymer-lipid conjugate.
Absstract of: CN120091992A
The present invention relates to a cationic lipid and a method for preparing the same, and more specifically, to a cationic lipid which can easily form a complex with an anionic drug and thus can be used for drug delivery, and a method for preparing the same.
Absstract of: CN120827534A
本发明公开了一种靶向PD‑L1蛋白降解的纳米颗粒及其制备方和应用。所述纳米颗粒包括透明质酸和BMS‑8分子的缀合物。本发明设计透明质酸和BMS‑8分子的缀合，构建一种新型的基于溶酶体降解体系(LYTAC技术)的双靶向纳米颗粒，能够特异性地与肿瘤细胞表面的PD‑L1蛋白结合，当纳米颗粒与肿瘤细胞表面的PD‑L1蛋白结合后，通过内吞作用被细胞摄取，随后被转运至溶酶体，触发PD‑L1蛋白的降解过程，高效降解PD‑L1蛋白，为肿瘤治疗提供了一种新的、有前景的方法。
Absstract of: CN120829386A
本发明涉及局部递送药物的材料及其应用。具体提供包含脂质组分的纳米颗粒组合物，所述脂质组分包含式(I)化合物。本发明纳米颗粒组合物仅在施用部位递送。
Absstract of: CN120112642A
The invention discloses gRNA (guide ribonucleic acid) targeting VEGFA (vascular endothelial growth factor A), a gene editing system and application of the gRNA. The gRNA of the present disclosure comprises a guide sequence having at least 80% sequence identity as compared to any of SEQ ID NO: 10-18, 40-230. The gene editing system disclosed by the invention comprises the gRNA disclosed by the invention and a coding sequence thereof, and RNA-guided nuclease and a coding sequence thereof.
Absstract of: US2025326810A1
Provided herein are novel constructs comprising gold nanoparticles bound to two types of cytokines, wherein the two types of cytokines comprise Tumor Necrosis Factor alpha (TNFα) and a cytokine selected from the group consisting of Interferon gamma (IFNγ) and Interleukin-12.
Absstract of: WO2025217739A1
There is provided pharmaceutical compositions comprising disulfiram (DSF) or copper di-ethyldithiocarbamate (CuET), an indirubin compound such as 6-bromo-indirubin-3'-oxime (BIO), and a stabilizer, wherein the disulfiram or CuET, the indirubin compound, and the stabilizer are associated with a lipid nanoparticle. The pharmaceutical compositions are particularly suitable for treating a cancer overexpressing p97 and NPLOC4.
Absstract of: US2025326708A1
The present disclosure relates to the field of medicine, specifically to a long-acting spleen-targeting cationic lipid compound comprising a benzene ring structure, a composition comprising the same, and a use thereof. More specifically, the present disclosure provides a compound of formula (I), or an N-oxide thereof, a solvate thereof, a pharmaceutically acceptable salt thereof, or a stereoisomer thereof. The present disclosure further provides a composition comprising the aforementioned compound and a use thereof in delivering therapeutic or prophylactic agents.
Absstract of: US2025325757A1
A cosmetic treatment method includes: applying, to skin or hair, an external preparation including a predetermined active ingredient and a base, and at least one of the active ingredient and the base contains fine water that is uncharged and has a particle size of less than or equal to 50 nanometers. Therefore, the applied fine water enters the skin or hair to contribute to maintenance of moisturization, and at the same time, forms a route through which the active ingredient permeates, thereby promoting the permeation of the active ingredient; therefore, the permeability of the active ingredient can be more appropriately improved.
Absstract of: US2025325702A1
Compositions for gene modification related to base editor systems, and methods of using the same to treat or prevent conditions associated with the extracellular deposition in various tissues of amyloid fibrils formed by the aggregation of misfolded transthyretin (TTR) proteins. Such conditions include, but are not limited to, polyneuropathy due to hereditary transthyretin amyloidosis (hATTR-PN) and hereditary cardiomyopathy due to transthyretin amyloidosis (hATTR-CM), both associated with autosomal dominant mutations of the TTR gene, and an age-related cardiomyopathy associated with wild-type TTR proteins (ATTRwt), also known as senile cardiac amyloidosis.
Absstract of: US2025325695A1
The present invention provides a method of a prophylaxis or a treatment of a pathological change of Bruch's membrane and/or an adjacent tissue, including a retinal pigment epithelium, a choroid, and an optic nerve head of an eye, e.g. a calcification of Bruch's membrane and/or the adjacent tissue, using a nanoparticle comprising a scaffold comprising a biodegradable material, an antibody targeted to a component of a Bruch's membrane, a component of a sub-retinal pigment epithelial deposit, or a component of an optic nerve head, and an anti-calcifying agent. Additionally, the present invention provides a pharmaceutical composition comprising said nanoparticle and one or more pharmaceutical acceptable excipient(s). Said pharmaceutical composition could be used in a method of prophylaxis or treatment of a pathological change of Bruch's membrane and/or adjacent tissues, including a retinal pigment epithelium and a choroid of an eye and/or a calcified sub-retinal pigment epithelium deposit and/or a calcified drusen.
Absstract of: US2025325699A1
The invention features polypeptides containing nuclear localization sequences that can be used to deliver polynucleotides to a cell. The polypeptides can be formulated with a polynucleotide and a lipid.
Absstract of: US2025325655A1
A vaccine adjuvant, and a preparation method therefor and a use thereof. The vaccine adjuvant is a MA105 immunologic adjuvant, and comprises (1) QS-21:50 μg/ml to 300 μg/ml; (2) Poly I:C: 400 μg/mL to 3000 μg/mL; and (3) lipid molecules constituting a vector, the vector being a mixture of a cationic liposome and a neutral liposome.
Nº publicación: US2025325513A1 23/10/2025
Applicant:
SHENYANG PHARMACEUTICAL UNIV [CN]
SHENYANG PHARMACEUTICAL UNIVERSITY
Absstract of: US2025325513A1
The present invention relates to a cabazitaxel prodrug anti-tumor preparation, designs and synthesizes a small molecule cabazitaxel prodrug with branched fatty alcohol involving formulas (I), (II) and (III) and containing different fatty alcohol side chains and different linking chains, and prepares a self-assembled nanoparticle. Results showed that the self-assembled nanoparticle of the small molecule cabazitaxel prodrug with branched fatty alcohol can effectively improve the efficacy of cabazitaxel, reduce toxic and side effects. The length of branched fatty alcohol side chains, the structure of the fatty alcohol side chains, the elemental composition of the linking chains and the length of the linking chains significantly affect preparation properties, in vivo fate and anti-tumor activity of the cabazitaxel-branched fatty alcohol prodrug self-assembled nanoparticle, which exhibits higher anti-tumor activity and lower toxicity compared with the self-assembled nanoparticle of small molecule cabazitaxel prodrug with straight-chain fatty alcohol.
BOPI
Electronic site
